课题基金 / 基金详情

CSHL 2023 Conference on Biology of Cancer: Microenvironment & Metastasis

CSHL 2023 Conference on Biology of Cancer: Microenvironment & Metastasis
CSHL 2023癌症生物学会议:微环境
批准号:
10750261
负责人:
DAVID J. STEWART
金额:
$1.5万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-08-01 至 2024-07-31

项目摘要

项目成果

DAVID J. STEWART的其他基金

相似基金

相关文献

中文摘要
翻译
癌症生物学:微环境与转移 纽约冷泉港 2023年9月19日至23日 摘要 癌症现在被认为是一种异常的器官,其中多种细胞类型在肿瘤发生时相互作用。 癌症起始和转移进展。在确定 肿瘤细胞中的遗传、表观遗传和代谢改变,并表征不同细胞 组成肿瘤的细胞类型,了解这些细胞类型相互作用的机制 相互合作,开发肿瘤变化的成像方法,探索治疗方法, 考虑到非恶性细胞的机会。因此,出现了一个 需要一种综合的方法来控制癌症。然而,大多数癌症会议 有组织地集中在肿瘤生物学的许多方面中的一个或两个方面。的 拟议的会议采取综合办法,建立一个平台, 癌症生物学、遗传学、表观遗传学、代谢、信号传导、 免疫学,诊断学和治疗学,讨论最新发现并促进对话 旨在解决临床上阻止持久反应的主要问题。我们认为 这种综合方法将引发跨学科的讨论和互动, 并找到新的方法来开发和提供新的治疗策略, 癌 这个两年一度的会议的第七次演出将吸引来自学术实验室的参与者, 研究机构和生物技术/制药行业,并将包括该领域的领导者, 成立调查员,初级教师,博士后研究员,研究生和企业 科学家为了确保展示最前沿的成果,许多演讲者将 根据提交给会议协调员和届会的摘要的质量选择 会议前几个月举行。我们的重点将放在未发表的结果上。到 最大限度地扩大参与,努力吸收杰出的女科学家 以及来自国外的科学家担任会议主席和特邀发言人。每届会议将 由组织者挑选的该领域的两名顶尖科学家主持。口头陈述将 由会议主席与组织者协商,从提交的摘要中选出。 选定的演讲者将包括研究生,博士后研究员和初级教师, 最大限度地吸收年轻的研究人员。此外,为了促进对下一个 一代科学家,一个晚突破会议将与邀请早期职业生涯组装 研究人员讨论癌症生物学的令人兴奋的进展。特别重要的是, 海报会议和小组讨论。海报会议为许多人提供了一个机会 请与会者在有利于非正式讨论的气氛中介绍其工作, 小组讨论会邀请思想领袖和与会者就一个备受争议的主题进行讨论, 个性化癌症药物在改善癌症治疗中的作用。会议 将是中等规模,我们预计约300人参加,其中绝大多数人 将展示海报或演讲。
英文摘要
Biology of Cancer: Microenvironment & Metastasis Cold Spring Harbor, New York September 19 – 23, 2023 ABSTRACT Cancer is now recognized as an abnormal organ where multiple cell types cooperate during cancer initiation and metastatic progression. Enormous progress has been made on identifying genetic, epigenetic and metabolic alterations in tumor cells and characterizing the different cell types composing a tumor, understanding the mechanisms by which these cell types interact with each other, developing ways to image the changes in a tumor and exploring therapeutic opportunities that take into account the non-malignant cells. Thus, there is an emergence of a need for an integrative approach for controlling cancer. However, most cancer meetings are organized to focus on one or two aspects of the many aspects of the biology of tumor. The proposed meeting takes an integrative approach to create a platform and bring together world leaders in different aspects of cancer biology, genetics, epigenetics, metabolism, signaling, immunology, diagnostics, and therapeutics to discuss the latest findings and promote dialogue aimed at solving the chief problems that prevent durable responses in the clinic. We believe that such an integrative approach will trigger discussions and interactions that cross the disciplinary borders and find new ways to develop and deliver novel therapeutic strategies for controlling cancer. The seventh rendition of this biennial conference will draw participants from academic labs, research institutes and biotech/pharmaceutical industries, and will include leaders in the field, established investigators, junior faculty, postdoctoral fellows, graduate students and corporate scientists. To ensure the presentation of the most cutting edge results many speakers will be chosen based on the quality of abstracts submitted to the meeting coordinators and session chairs several months prior to the meeting. Our emphasis will be on unpublished results. To maximize broad participation, efforts have been made to include outstanding women scientists and scientists from abroad as session chairs and invited speakers. Each session will be chaired by two leading scientists in the field selected by the organizers. Oral presentations will be selected from submitted abstracts by the session chairs in consultation with the organizers. Selected speakers will include graduate students, postdoctoral fellows and junior faculty aiming for maximal inclusion of young investigators. In addition, to promote recognition of the next generation of scientists, a late breaking session will be assembled with invited early career investigators to discuss exciting advances in cancer biology. Of special importance are the two poster sessions and panel discussion. The poster session provide an opportunity for many participants to present their work in an atmosphere conducive to informal discussion and the panel discussion engages thought leaders and the participants on one highly debated topic on the role played by personalized cancer medicine in improving cancer treatment. The meeting will be of moderate size and we expect about 300 people to attend, the vast majority of whom will be presenting a poster or talk.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CSHL Single Cell Analysis Course (2023-2027)
  • 批准号:
    10627446
  • 项目类别:
  • 资助金额:
    $16.16万
  • 财政年份:
    2023
  • 负责人:
    DAVID J. STEWART
  • 依托单位:
CSHL 2023 Eukaryotic DNA Replication and Genome Maintenance Conference
  • 批准号:
    10677192
  • 项目类别:
  • 资助金额:
    $1.66万
  • 财政年份:
    2023
  • 负责人:
    DAVID J. STEWART
  • 依托单位:
CSHL 2023 Eukaryotic mRNA Processing Conference
  • 批准号:
    10679367
  • 项目类别:
  • 资助金额:
    $1.5万
  • 财政年份:
    2023
  • 负责人:
    DAVID J. STEWART
  • 依托单位:
CSHL 2023 Brain Barriers Conference
  • 批准号:
    10608583
  • 项目类别:
  • 资助金额:
    $1.5万
  • 财政年份:
    2023
  • 负责人:
    DAVID J. STEWART
  • 依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: